New genetic drug targets fatty liver disease in early human trial

NCT ID NCT05648214

Recruiting now Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated Apr 30, 2026 · Updated 19 times

Summary

This early-stage study tests an experimental drug called ALN-PNP in healthy adults and people with a type of fatty liver disease (MASLD) who have a specific gene variant. The main goal is to check safety and how the body processes the drug. Researchers will also measure changes in liver fat and look for side effects over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

California Clinical Trials Medical Group
COMPLETED

Glendale, California, 91206, United States
Genoma Research Group, Inc
RECRUITING

Miami, Florida, 33173, United States
Med Research of Florida, LLC
RECRUITING

Miami, Florida, 33186, United States
Pioneer Research Solutions
RECRUITING

Houston, Texas, 77099, United States
Tandem Clinical Research
RECRUITING

Marrero, Louisiana, 70072, United States
Velocity Clinical research
RECRUITING

Los Angeles, California, 90057, United States

Conditions

Explore the condition pages connected to this study.

HEALTHY VOLUNTEERS HEALTHY VOLUNTEERS METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)